After asthma: redefining airways diseases
University of Oxford · Oxford BioMedica (United Kingdom) · +35 more institutions
Abstract
Momentum to the recent encouraging progress in new drug discovery and, as did the first asthma guidelines published 27 years ago, 14-17 lead to a decade or more of improved outcomes. We conclude the Commission with seven key recom mendations and summarise our views on how these could be developed to benefit patients with asthma (panel 1).
Citation impact
- FWCI
- 65.64
- Percentile
- 100%
- References
- 339
Authors
23- IPIan PavordCorresponding
University of Oxford, Oxford BioMedica (United Kingdom)
- RBRichard Beasley
Medical Research Institute of New Zealand
- ÀAÀlvar Agustí
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
- GPGary P. Anderson
The University of Melbourne
- EHElisabeth H. Bel
Amsterdam UMC Location University of Amsterdam, University of Amsterdam
Topics & keywords
- Asthma
- Medicine
- Small airways
- Intensive care medicine
- Immunology
- Good health and well-being
Funding
- AAmgen
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- TPTeva Pharmaceutical Industries
- FHF. Hoffmann-La Roche
- RPRegeneron Pharmaceuticals
- MMMassachusetts Medical Society
- ECEuropean Commission
- IUInternational Union Against Tuberculosis and Lung Disease
- MCMerck Canada
- NINational Institutes of Health
- GGenentech
- NPNovartis Pharmaceuticals UK Limited
- MRMedical Research CouncilAwards: MR/K002449/2, MR/M016579/1
- NHNational Health and Medical Research Council
- HRHealth Research Council of New Zealand
- NINational Institute of Allergy and Infectious Diseases